8-K: Atara Biotherapeutics Announces Leadership Transition and Positive Clinical Trial Updates

Atara Biotherapeutics announced a leadership transition, with Pascal Touchon stepping down as CEO to become Chairman, and Cokey Nguyen promoted to CEO, alongside positive clinical trial updates and financial results.

Summary

• Atara Biotherapeutics reported its second quarter 2024 financial results, highlighting a leadership transition and progress in its clinical programs.
• Pascal Touchon will step down as President and CEO, effective September 9, 2024, to become Chairman of the Board.
• AnhCo (Cokey) Nguyen, Ph.D., currently Chief Scientific and Technical Officer, will be appointed President and CEO on the same date.
• The company's Biologics License Application (BLA) for tab-cel has been accepted by the FDA with a priority review and a PDUFA action date of January 15, 2025.
• A Phase 1 study of ATA3219 for lupus nephritis is expected to begin in Q4 2024, with initial data expected in mid-2025.
• A study of ATA3219 for non-Hodgkin's lymphoma is currently enrolling, with initial data expected in Q1 2025.
• Atara received a $20 million milestone payment from Pierre Fabre for the tab-cel BLA acceptance and anticipates a further $60 million upon FDA approval.
• The company also entered an agreement with Pierre Fabre for a $15.5 million purchase of tab-cel intermediate inventory.
• Atara's cash, cash equivalents, and short-term investments totaled $35.3 million as of June 30, 2024, with total available funds of $73.2 million when including receivables and payments from Pierre Fabre.
• The company expects full-year 2024 operating expenses to decrease by approximately 35% from 2023.
• Atara anticipates its current cash runway will fund operations into 2027.

Sentiment

Score: 8

Explanation: The document presents a generally positive outlook with significant progress in clinical trials, a strong financial position, and a strategic leadership transition. The company's cash runway into 2027 and the potential for tab-cel approval are strong positives. While there are risks associated with clinical development and regulatory approvals, the overall tone is optimistic.

Positives

• The FDA's acceptance of the tab-cel BLA with priority review significantly increases the likelihood of approval.
• The $20 million milestone payment and $15.5 million inventory purchase from Pierre Fabre strengthen Atara's financial position.
• The company's cash runway extending into 2027 provides financial stability for ongoing operations and clinical trials.
• The planned 35% reduction in operating expenses for 2024 demonstrates a commitment to financial efficiency.
• The progress of ATA3219 into clinical trials for lupus nephritis and non-Hodgkin's lymphoma shows advancement in the company's pipeline.
• The leadership transition is presented as a positive move, with the current CEO moving to Chairman and the promotion of the current Chief Scientific Officer to CEO.

Negatives

• The company reported a net loss of $19.0 million for the second quarter of 2024, although this is a significant improvement compared to the $71.1 million loss in the same period of 2023.
• Cash, cash equivalents, and short-term investments decreased from $46.2 million on March 31, 2024, to $35.3 million on June 30, 2024.

Risks

• The success of the tab-cel BLA is not guaranteed, and FDA approval is contingent on the agency's review.
• Clinical trials for ATA3219 may not yield positive results, and the development of these therapies is subject to regulatory and clinical risks.
• The company's financial projections are based on certain assumptions, including the receipt of milestone payments and royalties, which may not materialize.
• The company's ability to fund operations into 2027 is dependent on continued cost reductions and the success of its clinical programs.
• The transition of tab-cel activities to Pierre Fabre may present operational challenges.

Future Outlook

Atara expects its current cash runway to fund planned operations into 2027, supported by milestone payments, inventory purchases, and cost reductions. The company anticipates the transition of tab-cel activities to Pierre Fabre will further reduce operating expenses. They also anticipate royalties from sales of tab-cel by Pierre Fabre in the U.S. post BLA approval.

Management Comments

• Pascal Touchon stated that the company is making significant progress with the FDA towards the target action date for tab-cel and is advancing the clinical development of ATA3219.
• Pascal Touchon mentioned his decision to move into the role of Chairman for personal reasons, to dedicate more time to his family.
• Cokey Nguyen expressed his honor to serve as Atara's CEO and his commitment to getting tab-cel approved in the U.S. and unlocking the potential of the allogeneic CAR-T platform.

Industry Context

This announcement comes at a time of increasing interest in cell therapies, particularly allogeneic approaches, which offer the potential for off-the-shelf treatments. Atara's progress with tab-cel and ATA3219 positions them as a key player in this space, with the potential to address unmet needs in cancer and autoimmune diseases. The leadership transition also reflects a strategic shift as the company moves closer to potential commercialization.

Comparison to Industry Standards

• Atara's tab-cel is the first allogeneic T-cell therapy to receive regulatory approval globally, setting a new benchmark in the field.
• The company's approach to allogeneic CAR-T therapy, which maintains the native T-cell receptor without gene editing, is a differentiated approach compared to other companies using gene-editing technologies like CRISPR, such as CRISPR Therapeutics and Editas Medicine.
• The clinical data for tab-cel, with a 48.8% Objective Response Rate (ORR) in the ALLELE study, is competitive with other cell therapies in similar indications, such as autologous CAR-T therapies like those from Gilead (Yescarta) and Novartis (Kymriah).
• The development of ATA3219 for autoimmune diseases like lupus nephritis is a novel approach, as most CAR-T therapies are focused on oncology. This positions Atara to potentially address a significant unmet need in autoimmune disease, where current treatments are often limited.
• The company's focus on reducing manufacturing costs and improving the safety profile of allogeneic CAR-T therapies aligns with industry trends towards more accessible and safer cell therapies.

Management Changes

Related Party Transactions

• Atara entered into an agreement with Pierre Fabre for Pierre Fabre to purchase certain existing tab-cel intermediate inventory from Atara for $15.5 million.

Stakeholder Impact

• Shareholders will likely view the leadership transition and positive clinical trial updates favorably.
• Employees may experience changes due to the leadership transition and the planned transfer of tab-cel activities to Pierre Fabre.
• Patients with cancer and autoimmune diseases may benefit from the potential approval of tab-cel and the development of ATA3219.
• Pierre Fabre, as a partner, will be impacted by the transition of tab-cel activities and the potential commercialization of the therapy.
• Suppliers and creditors may be impacted by the company's financial performance and operational changes.

Next Steps

• Atara will continue to work with the FDA on the review of the tab-cel BLA.
• The company will initiate the Phase 1 study of ATA3219 for lupus nephritis in Q4 2024.
• Atara will continue enrolling patients in the ATA3219 non-Hodgkin's lymphoma study.
• The company will prepare for the potential U.S. launch of tab-cel with its partner Pierre Fabre.
• Atara will transition substantially all activities relating to tab-cel to Pierre Fabre, potentially as early as Q1 2025.
• Atara is progressing toward an IND submission for ATA3431 in H2 2025.

Key Dates

Keywords

Atara Biotherapeutics, tab-cel, ATA3219, allogeneic T-cell therapy, CAR-T, Epstein-Barr virus, EBV, lupus nephritis, non-Hodgkins lymphoma, FDA, BLA, PDUFA, Pierre Fabre, leadership transition, clinical trials, immunotherapy